Study identifier:176334-0307
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A multicentre randomised trial to compare the effect of two blinded doses of CASODEX (AstraZeneca 176,334; 100 mg and 150 mg orally daily) and castration in the treatment of advanced carcinoma of the prostate
prostate cancer
Phase 3
-
-
-
-
Interventional
-
Allocation: - 
Endpoint Classification: - 
Intervention Model: - 
Masking: - 
Primary Purpose: - 
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
| Arms | Assigned Interventions | 
|---|